Africa: HIV Science Races Ahead As Funding Crisis Threatens to Widen Access Gap

What the report says

AllAfrica, carrying a report from The Independent in Kampala dated July 29, 2026, says HIV research is advancing rapidly while instability in international financing threatens access to care and prevention. The report frames the issue as a widening split between scientific progress and the funding systems that have helped make HIV a manageable chronic illness for millions over the past two decades.

According to the report, recent disruptions to PEPFAR-supported programmes followed a January 2025 U.S. foreign assistance pause and related stop-work orders after President Donald Trump returned to office. Although some exemptions were later made for life-saving and HIV services, studies cited by the article found broad effects: a survey of 166 implementing partners in 46 countries reported lost funding awards, restrictions on activities and closures of HIV service sites, while another analysis found 77,163 fewer children receiving PEPFAR-backed treatment globally in the 2025 financial year than the year before.

The article also highlights promising developments presented by researchers, including lenacapavir, a twice-yearly injectable medicine for HIV prevention. In an open-label extension of the PURPOSE 1 study among women in Uganda and South Africa, no new infections were recorded in the first 52 weeks among participants receiving the drug, and most chose to continue it. Researchers also reported encouraging results for a once-weekly oral treatment combining islatravir and lenacapavir for adults whose HIV was already suppressed.

The significance, as presented by The Independent, is that new tools may not reduce infections or improve treatment unless they are affordable, financed and delivered to affected communities. The report also notes continuing research challenges, including evidence of HIV-related immune activity in spinal fluid among some adolescents despite undetectable virus in blood tests.